Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDRiver EOC 302: tuvusertib combinations or monotherapy in PARPi-progressed epithelial ovarian cancer
NL-OMON59669Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tuvusertib, niraparib and lartesertib in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Merck KGaA. Primary endpoints: Confirmed objective response and Treatment-emergent adverse events. Started Apr 2025; status: completed.
02
Drugs
tuvusertibnirapariblartesertib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON59669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59669.